ADC Shows Effectiveness in SCLC.
Results from a phase I trial presented during the 2015 European Cancer Congress suggest that an experimental antibody-drug conjugate, rovalpituzumab tesirine, may be effective against recurrent small cell lung cancer, for which there are few treatment options.
D000911:Antibodies, Monoclonal / Q000276:immunology; D001569:Benzodiazepines / Q000008:administration & dosage; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008565:Membrane Proteins / Q000276:immunology; D011758:Pyrroles / Q000008:administration & dosage; D019233:Retreatment; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; C496666:DLL3 protein, human; D018796:Immunoconjugates; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D011758:Pyrroles; C438462:pyrrolo(2,1-c)(1,4)benzodiazepine; D001569:Benzodiazepines